Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Re-randomized Study To Assess the Efficacy and Safety With Hemay005 Tablets in Chinese Patients With Moderately to Severely Active Ulcerative Colitis

NCT07650942 is registered in ClinicalTrials.gov with Ganzhou Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07650942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07650942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Re-randomized Study To Assess the Efficacy and Safety With Hemay005 Tablets in Chinese Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
February 28, 2029
Enrollment
360 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis (uc)